Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Cardiovascular | 1,118.2 | 1,043.2 | 934.2 | 961.0 | 849.5 | 700.6 | | 520.9 |
| International | 500.4 | 465.9 | 413.8 | 419.1 | 386.3 | 307.1 | | |
| CHINA | 149.3 | 138.2 | 113.2 | 113.3 | 92.7 | 73.4 | | |
| Endoscopy | 32.8 | 31.5 | 29.7 | 33.9 | 33.3 | 27.2 | | 21.2 |
| Total revenues | 1,151.0 | 1,074.8 | 963.9 | 994.9 | 882.8 | 727.9 | 603.8 | 542.1 |
| Revenue growth [+] | 7.1% | 11.5% | -3.1% | 12.7% | 21.3% | 20.5% | 11.4% | 6.4% |
| Cardiovascular | 7.2% | 11.7% | -2.8% | 13.1% | 21.2% | | | 5.9% |
| International | 7.4% | 12.6% | -1.3% | 8.5% | 25.8% | | | |
| CHINA | 8.0% | 22.1% | -0.1% | 22.2% | 26.3% | | | |
| Endoscopy | 3.9% | 6.2% | -12.4% | 1.8% | 22.2% | | | 18.1% |
| Cost of goods sold | 631.9 | 589.4 | 562.7 | 562.5 | 488.0 | 401.6 | 338.8 | 306.4 |
| Gross profit | 519.1 | 485.3 | 401.2 | 432.4 | 394.8 | 326.3 | 265.0 | 235.8 |
| Gross margin | 45.1% | 45.2% | 41.6% | 43.5% | 44.7% | 44.8% | 43.9% | 43.5% |
| Selling, general and administrative | 342.5 | 335.7 | 297.7 | 327.3 | 276.0 | 229.1 | 184.4 | 156.3 |
| Research and development | 75.5 | 71.2 | 57.5 | 65.6 | 59.5 | 51.4 | 45.2 | 40.8 |
| Other operating expenses | 4.6 | 13.2 | 10.7 | -0.2 | -0.1 | 11.8 | 0.1 | 1.1 |
| EBITDA [+] | 178.3 | 149.3 | 129.3 | 131.8 | 128.8 | 87.5 | 79.1 | 75.0 |
| EBITDA growth | 19.4% | 15.5% | -1.9% | 2.3% | 47.3% | 10.6% | 5.5% | -2.9% |
| EBITDA margin | 15.5% | 13.9% | 13.4% | 13.2% | 14.6% | 12.0% | 13.1% | 13.8% |
| Depreciation | 33.4 | 34.5 | 35.5 | 31.4 | 28.3 | 26.8 | 24.5 | 22.6 |
| EBITA | 144.9 | 114.8 | 93.8 | 100.4 | 100.5 | 60.7 | 54.6 | 52.3 |
| EBITA margin | 12.6% | 10.7% | 9.7% | 10.1% | 11.4% | 8.3% | 9.0% | 9.7% |
| Amortization of intangibles | 48.4 | 49.6 | 58.6 | 60.7 | 41.2 | 26.8 | 19.3 | 14.8 |
| EBIT [+] | 96.5 | 65.2 | 35.2 | 39.7 | 59.3 | 33.9 | 35.3 | 37.5 |
| EBIT growth | 47.9% | 85.3% | -11.4% | -33.0% | 75.0% | -4.1% | -5.9% | -9.0% |
| EBIT margin | 8.4% | 6.1% | 3.7% | 4.0% | 6.7% | 4.7% | 5.9% | 6.9% |
| Non-recurring items [+] | 8.9 | 4.3 | 36.8 | 24.3 | 0.7 | 0.8 | 0.5 | |
| Asset impairment | 2.2 | 4.3 | 36.5 | 23.8 | 0.7 | 0.8 | | |
| In-process research & development | 6.7 | | 0.3 | 0.5 | | | 0.5 | |
| Interest expense, net [+] | 5.9 | 4.5 | 9.4 | 12.1 | 9.2 | 7.4 | 8.7 | 6.0 |
| Interest expense | 6.3 | 5.3 | 10.0 | 12.4 | 10.4 | 7.7 | 8.8 | 6.2 |
| Interest income | 0.4 | 0.8 | 0.6 | 0.3 | 1.2 | 0.4 | 0.1 | 0.3 |
| Other income (expense), net [+] | 1.0 | -2.5 | -2.3 | -1.1 | 0.1 | 10.2 | -0.8 | -0.4 |
| Gain (loss) on acquisitions / transactions | | | | | | 11.0 | | |
| Other | 1.0 | -2.5 | -2.3 | -0.5 | 0.1 | -0.9 | -0.8 | -0.4 |
| Pre-tax income | 82.6 | 53.9 | -13.2 | 2.2 | 49.5 | 35.9 | 25.4 | 31.2 |
| Income taxes | 8.1 | 5.5 | -3.4 | -3.3 | 7.5 | 8.4 | 5.3 | 7.4 |
| Tax rate | 9.8% | 10.1% | 25.6% | | 15.1% | 23.3% | 20.7% | 23.7% |
| Net income | 74.5 | 48.5 | -9.8 | 5.5 | 42.0 | 27.5 | 20.1 | 23.8 |
| Net margin | 6.5% | 4.5% | -1.0% | 0.5% | 4.8% | 3.8% | 3.3% | 4.4% |
| |
| Basic EPS [+] | $1.31 | $0.86 | ($0.18) | $0.10 | $0.80 | $0.56 | $0.45 | $0.54 |
| Growth | 52.0% | -586.0% | -279.4% | -87.7% | 42.5% | 24.5% | -16.2% | 1.5% |
| Diluted EPS [+] | $1.29 | $0.84 | ($0.18) | $0.10 | $0.78 | $0.55 | $0.45 | $0.53 |
| Growth | 53.0% | -575.7% | -283.2% | -87.6% | 41.8% | 22.5% | -16.1% | 1.0% |
| |
| Shares outstanding (basic) [+] | 56.8 | 56.1 | 55.4 | 55.1 | 52.3 | 48.8 | 44.4 | 44.0 |
| Growth | 1.2% | 1.3% | 0.7% | 5.4% | 7.1% | 9.9% | 0.8% | 2.1% |
| Shares outstanding (diluted) [+] | 57.7 | 57.4 | 55.4 | 56.2 | 53.9 | 50.1 | 44.9 | 44.5 |
| Growth | 0.5% | 3.5% | -1.4% | 4.3% | 7.6% | 11.7% | 0.8% | 2.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|